Sep 2026· Allergy. European Journal of Allergy and Clinical Immunology· 0 citations· 27 references
Medicine
TL;DR
A substantial subset of individuals with symptom-based remission still showed signs of type two inflammation or reduced lung function, indicating that absence of symptoms does not necessarily reflect complete disease resolution.
Abstract
Background
The long-term prognosis of childhood asthma remains uncertain. We aimed to (1) assess the prevalence of asthma remission from childhood to young adulthood, (2) identify associated factors, and (3) evaluate whether symptom-based remission was related to objective markers of inflammation and lung function.
Materials And Methods
We analyzed data from 2698 participants in the Swedish population-based BAMSE birth cohort, followed up to age 24 years with questionnaires and clinical examinations. Symptom-based remission was defined as absence of asthma symptoms and medication in the preceding year. Clinical remission also required no hospital visits and optimization of lung function (postbronchodilator forced expiratory volume in 1 s ≥ 80%). Complete remission required normal eosinophil counts (< 0.3 × 109/L) and fractional exhaled nitric oxide levels (< 40 ppb).
Results
Among 257 participants with asthma at age 8 years, 39% achieved symptom-based remission, 29% clinical remission, and 18% complete remission at age 24 years. Male sex increased the likelihood of symptom-based remission (odds ratio [OR] 2.4, 95% confidence interval [CI] 1.3-4.5), whereas food sensitization (OR 0.3, 95% CI 0.3-0.6) and overweight/obesity (OR 0.4, 95% CI 0.2-0.9) decreased it. Among individuals in symptom-based remission, 27% displayed abnormal results in at least one objective marker.
Conclusions
Four of 10 participants with asthma in childhood achieved symptom-based remission by young adulthood, but rates declined when stricter, objective definitions were applied. A substantial subset of individuals with symptom-based remission still showed signs of type two inflammation or reduced lung function, indicating that absence of symptoms does not necessarily reflect complete disease resolution.
Clinical remission is an emerging treatment goal in severe asthma, although real-world data on its long-term maintenance remain limited. We retrospectively evaluated 50 patients who initiated first-line biologic therapy with omalizumab, mepolizumab, or reslizumab between 2015 and 2019. Clinical remission at 12 months w...
Elena Dorado-Fonseca, Julia García de Pedro, Z. Ji et al.· Open Respiratory Archives· 0 citations
RATIONALE
The efficacy of biologics remains debatable in current or ex- smokers with severe asthma.
OBJECTIVES
This study aimed to evaluate responses to biologics by smoking exposure and to assess variations in management practice across Europe.
METHODS
This was a retrospective real-world study of adults with sever...
M. Caminati, J. Charriot, A. Bansal et al.· American Journal of Respirat...· 1 citation
BACKGROUND
Few studies have assessed the long-term prognosis of work-related asthma (WRA).
OBJECTIVE
We evaluated outcomes in WRA patients after specific inhalation challenge (SIC), including remission rates and factors associated with poor outcomes. Cases with positive SIC were diagnosed as occupational asthma.
ME...
H. Suojalehto, Jussi Lantto, O. Kailari et al.· Journal of Allergy and Clini...· 0 citations
INTRODUCTION
Asthma prevalence is rising in Africa; yet reliable and contemporary prevalence data are unavailable for many countries. Moreover, prevalence estimates are typically based on symptom questionnaires, which may lead to misclassification of disease burden. This study aims to determine the prevalence, severity...
O. Ozoh, Sandra Kwarteng Owusu, R. Nantanda et al.· Thorax· 0 citations
Background. Late-onset asthma (after 40 years) is characterized by more severe disease, frequent exacerbations, fixed bronchial obstruction, and high comorbidity; prognostic tools for this age group, including risk models for rehospitalization and mucus plugs, remain insufficiently developed.
Aim. To develop and valid...
T. U. Bogatyreva, V. Gaynitdinova, E. S. Aynetdinova et al.· Consilium Medicum· 0 citations
BACKGROUND
Uncontrolled asthma symptoms and prior-year exacerbations increase the risk for future exacerbations in school-aged children. The Pediatric Asthma Impairment and Risk Questionnaire (Peds-AIRQ) is an 8-item, equally weighted, yes/no asthma control tool validated for children aged 5-11 years that assesses curr...
Leonard B. Bachelier, B. Chipps, K. Coyne et al.· Annals of Allergy, Asthma &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.